Kynurenine Pathway and Quinolinic Acid Excitotoxicity: The “Fog Machine”

When tryptophan is shunted into the kynurenine pathway by IDO-1 (induced by IFN-\(\gamma\) and other inflammatory mediators), downstream metabolites diverge into neuroprotective (kynurenic acid) versus neurotoxic (quinolinic acid, 3-hydroxykynurenine) branches. This section argues that in ME/CFS, the balance is shifted toward neurotoxic metabolites, producing NMDA receptor overstimulation, excitotoxic neural stress, and the characteristic cognitive dysfunction. This pathway mechanistically connects immune activation to brain fog.

ImportantHypothesis: Quinolinic Acid Excitotoxicity in ME/CFS

Proinflammatory cytokines (IFN-\(\gamma\), IL-1\(\beta\), TNF-\(\alpha\)) upregulate IDO-1, diverting tryptophan from serotonin synthesis into the kynurenine pathway (Huang et al. 2020) (Kavyani et al. 2022). Downstream, kynurenine monooxygenase (KMO) converts kynurenine to 3-hydroxykynurenine and ultimately to quinolinic acid (QUIN), a potent NMDA receptor agonist (Lugo-Huitrón et al. 2013). At sub-threshold concentrations, QUIN drives hippocampal dysfunction, oxidative stress, and mitochondrial injury rather than frank excitotoxic cell death, potentially explaining the cognitive impairment and dysexecutive symptoms in ME/CFS (Kavyani et al. 2022) (Dehhaghi et al. 2022). (Certainty: Medium. KP dysregulation in ME/CFS is replicated; direct QUIN measurement in brain parenchyma is technically challenging and understudied.)

ImportantHypothesis: KYNA–QUIN Balance and Brain Fog

Kynurenic acid (KYNA), produced by kynurenine aminotransferases (KAT) from kynurenine, is a broad-spectrum NMDA and \(\alpha\)-7 nicotinic receptor antagonist that counteracts QUIN toxicity (Bai et al. 2021) (Huang et al. 2020). However, elevated KYNA itself impairs cognition by suppressing cholinergic and dopaminergic neurotransmission. The net cognitive outcome in ME/CFS thus depends on the dynamic QUIN/KYNA ratio: when QUIN dominates, excitotoxic stress predominates; when KYNA dominates, a sedating “fog” effect predominates (Bai et al. 2021). (Certainty: Medium. Ratio hypothesis is mechanistically coherent; direct human data in ME/CFS is limited to peripheral measurements.)

References

Bai, Margaret Y., David B. Lovejoy, Gilles J. Guillemin, Ron Kozak, Trevor W. Stone, and Maju Mathew Koola. 2021. “Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders.” Complex Psychiatry 7 (1–2): 19–33. https://doi.org/10.1159/000515066.
Dehhaghi, Mohsen, Ekua W Brenu, Donald R Staines, and Sonya M Marshall-Gradisnik. 2022. “Kynurenine Pathway Metabolites and Their Association with Clinical Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.” Journal of Translational Medicine 20 (1): 20. https://doi.org/10.1186/s12967-021-03189-5.
Huang, Yu-Sheng, Joy Ogbechi, Felix I. Clanchy, Richard O. Williams, and Trevor W. Stone. 2020. IDO and Kynurenine Metabolites in Peripheral and CNS Disorders.” Frontiers in Immunology 11: 388. https://doi.org/10.3389/fimmu.2020.00388.
Kavyani, Zahra, Ekua W Brenu, Donald R Staines, and Sonya M Marshall-Gradisnik. 2022. “Kynurenine Pathway Metabolites in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Systematic Review.” Journal of Translational Medicine 20 (1): 512. https://doi.org/10.1186/s12967-022-03712-3.
Lugo-Huitrón, Rafael, Perla Ugalde Muñiz, Benjamín Pineda, José Pedraza-Chaverrí, Camilo Ríos, and Verónica Pérez-de la Cruz. 2013. “Quinolinic Acid: An Endogenous Neurotoxin with Multiple Targets.” Oxidative Medicine and Cellular Longevity 2013: 104024. https://doi.org/10.1155/2013/104024.